SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
Clin. transl. oncol. (Print)
; 25(9): 2634-2646, sept. 2023. tab, ilus
Article
in English
| IBECS
| ID: ibc-224130
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 510%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Brain Neoplasms
/
Glioma
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2023
Document type:
Article
Institution/Affiliation country:
Catalan Institute of Oncology/Spain
/
Complejo Asistencial Universitario de Salamanca/Spain
/
Complejo Hospitalario Universitario de Orense/Spain
/
Hospital Univeristari i Politècnic La Fe/Spain
/
Hospital Universitario Doctor Josep Trueta/Spain
/
Hospital Universitario Marqués de Valdecilla/Spain
/
Hospital de Sant Pau i La Santa Creu/Spain
/
Hospital del Mar/Spain
/
IDIBAPS/Spain
/
IdISCC/Spain